2006•CABI Publishing eBooksRequires access

Governing innovative science: challenges facing the commercialization of plant-made pharmaceuticals.

S. Smyth, George G. Khachatourians, Peter W.B. Phillips

Abstract

This chapter raises issues associated with gene flow in the case of plant-made pharmaceuticals (PMPs). Following an overview of the importance of PMPs, recent developments in this field and the possible environmental concerns are discussed. Recent developments include: plants with engineered pharmaceutical secondary metabolite products; plants with engineered immunotherapeutic products; and plants with engineered human pharmaceutical enzyme products. Existing PMP regulations in Canada and the USA are discussed, as well as recent industry-government regulatory collaborations.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Commercialization, Biotechnology, Pharmaceutical industry, Government (linguistics), Engineering, Business, Biology, Marketing